Announcements Trials
Browse Landscape

Phase

Phase 2 26Phase 3 11Phase 1 8Phase 1/2 5Phase 2/3 3Phase NA 2Phase 4 2

Status

Recruiting 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Lymphoid 3Other hematologic neoplasm 2

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 10Multiple Myeloma 8Leukemia 6Lung Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Burkitt Lymphoma 3Recurrence 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Neoplasms, Plasma Cell 2Lymphoma 2Leukemia, T-Cell 2Waldenstrom Macroglobulinemia 1Vomiting 1Uterine Cervical Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Mouth Neoplasms 1Lymphoma, Large B-Cell, Diffuse 1Lymphoma, B-Cell 1Leukemia, Myeloid, Acute 1Fatigue 1Congenital Abnormalities 1Breast Neoplasms 1Breast Carcinoma In Situ 1Brain Neoplasms 1

Interventions

blinatumomab 4Dexamethasone 3Vincristine 2Methotrexate 2Cyclophosphamide 2venetoclax 1tocilizumab 1siltuximab 1fludarabine phosphate 1epratuzumab 1Whole-Body Irradiation 1Thiotepa 1Radioimmunodetection 1Prednisone 1Melphalan 1Etoposide 1Diphenhydramine 1Daunorubicin 1Cytarabine 1Carboplatin 1Busulfan 1Asparaginase 1Antilymphocyte Serum 1Acetaminophen 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 2/3 × Burkitt Lymphoma × Dexamethasone × Clear all
NCT07570173 2026-05-26

MK-1045-005

Merck Sharp & Dohme LLC

Phase 2/3 Recruiting
340 enrolled
Lymphoid

Burkitt Lymphoma

NCT06882057 2025-08-26

CCCG-LR-B-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
3,000 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT06764238 2025-02-07

CCCG-I/HR-ALL

Institute of Hematology & Blood Diseases Hospital, China

Phase 2/3 Recruiting
1,800 enrolled
LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡